Nasdaq · CIK 0001574232
ADXN Addex Therapeutics Ltd.
Insider trading from SEC Form 4. Last filing 38 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at Addex Therapeutics Ltd., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 44 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Jason Raleigh Nunn director | DDisposition to issuer Common Stock | -219,561 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Roger Mills CHIEF MEDICAL OFFICER | DDisposition to issuer Common Stock | -392,837 | $0.00 | $0 | 393,139 | 38 d ago |
| Sep 2, 2026 | Raymond George Hill director | DDisposition to issuer Common Stock | -1,365,532 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -37,770 | $0.00 | $0 | 565,138 | 38 d ago |
| Sep 2, 2026 | Timothy Mark Dyer CHIEF EXECUTIVE OFFICER | DDisposition to issuer Common Stock | -16,413,787 | $0.00 | $0 | 435,192 | 38 d ago |
| Sep 2, 2026 | Vincent Michael Lawton director | DDisposition to issuer Common Stock | -2,507,487 | $0.00 | $0 | 500 | 38 d ago |
| Sep 2, 2026 | Isaac Manke director | DDisposition to issuer Common Stock | -219,561 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | DDisposition to issuer Common Stock | -306,765 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Vincent Michael Lawton director | AGrant or award Common Stock | +2,507,487 | $0.00 | $0 | 2,507,987 | 38 d ago |
| Sep 2, 2026 | Roger Mills CHIEF MEDICAL OFFICER | AGrant or award Common Stock | +392,837 | $0.00 | $0 | 785,976 | 38 d ago |
| Sep 2, 2026 | Jason Raleigh Nunn director | AGrant or award Common Stock | +219,561 | $0.00 | $0 | 219,561 | 38 d ago |
| Sep 2, 2026 | Isaac Manke director | AGrant or award Common Stock | +219,561 | $0.00 | $0 | 219,561 | 38 d ago |
| Sep 2, 2026 | Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | AGrant or award Common Stock | +306,765 | $0.00 | $0 | 306,765 | 38 d ago |
| Sep 2, 2026 | Raymond George Hill director | AGrant or award Common Stock | +1,365,532 | $0.00 | $0 | 1,365,532 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +37,770 | $0.00 | $0 | 602,908 | 38 d ago |
| Sep 2, 2026 | Timothy Mark Dyer CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +16,413,787 | $0.00 | $0 | 16,848,979 | 38 d ago |
| Sep 2, 2026 | Jason Raleigh Nunn director | DDisposition to issuer Stock-option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | DDisposition to issuer Stock-option (Right to Buy)derivative | -200,000 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -59,530 | $0.00 | $0 | 543,378 | 38 d ago |
| Sep 2, 2026 | Roger Mills CHIEF MEDICAL OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Isaac Manke director | DDisposition to issuer Stock-option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Timothy Mark Dyer CHIEF EXECUTIVE OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -3,369,796 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Vincent Michael Lawton director | DDisposition to issuer Stock-option (Right to Buy)derivative | -501,598 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Raymond George Hill director | DDisposition to issuer Stock-option (Right to Buy)derivative | -273,107 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +59,530 | $0.00 | $0 | 602,908 | 38 d ago |
| Sep 2, 2026 | Roger Mills CHIEF MEDICAL OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | 38 d ago |
| Sep 2, 2026 | Timothy Mark Dyer CHIEF EXECUTIVE OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +3,369,796 | $0.00 | $0 | 3,369,796 | 38 d ago |
| Sep 2, 2026 | Raymond George Hill director | AGrant or award Stock-option (Right to Buy)derivative | +273,107 | $0.00 | $0 | 273,107 | 38 d ago |
| Sep 2, 2026 | Vincent Michael Lawton director | AGrant or award Stock-option (Right to Buy)derivative | +501,598 | $0.00 | $0 | 501,598 | 38 d ago |
| Sep 2, 2026 | Jason Raleigh Nunn director | AGrant or award Stock-option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | 38 d ago |
| Sep 2, 2026 | Isaac Manke director | AGrant or award Stock-option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | 38 d ago |
| Sep 2, 2026 | Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | AGrant or award Stock-option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 592,908 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 602,908 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 572,908 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 602,908 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -65,620 | $0.00 | $0 | 537,288 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +65,620 | $0.00 | $0 | 602,908 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -90,529 | $0.00 | $0 | 512,379 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +90,529 | $0.00 | $0 | 602,908 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -208,974 | $0.00 | $0 | 393,934 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +208,974 | $0.00 | $0 | 602,908 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | DDisposition to issuer Stock-option (Right to Buy)derivative | -100,485 | $0.00 | $0 | 502,423 | 38 d ago |
| Sep 2, 2026 | Lenaic Nathanael Teyssedou PRINCIPAL ACCOUNTING OFFICER | AGrant or award Stock-option (Right to Buy)derivative | +100,485 | $0.00 | $0 | 602,908 | 38 d ago |
Insiders
Everyone who has filed a Form 4 here.
- Timothy Mark DyerCHIEF EXECUTIVE OFFICER
- Raymond George Hilldirector
- Mikhail KalinichevHEAD OF TRANSLATIONAL SCIENCE
- Vincent Michael Lawtondirector
- Isaac Mankedirector
- Roger MillsCHIEF MEDICAL OFFICER
- Jason Raleigh Nunndirector
- Lenaic Nathanael TeyssedouPRINCIPAL ACCOUNTING OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.